XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.21.2

Stockholders’ Deficit | 9 Months Ended
--- | ---
Sep. 30, 2021
Equity [Abstract] |
Stockholders’ Deficit | Note 9 – Stockholders’ Deficit At September 30, 2021, and prior to the conversions noted below, the Company had three (3) classes of stock: Common Stock
| - | 500,000,000 shares authorized
| - | Par value - $0.001
| - | Voting at 1 vote per share
Series A, Convertible Preferred Stock
| - | 100,000,000 shares authorized
| - | 13,000,000 issued and outstanding
| - | Par value - $0.001
| - | Voting at 10 votes per share (130,000,000 votes)
| - | Ranks senior to any other class of preferred stock
| - | Dividends - none
| - | Liquidation preference – none
| - | Rights of redemption - none
| - | Conversion into 1/10 of a share of common stock for each share held (1,300,000 common stock equivalents)
Series C, Convertible Preferred Stock
| - | 1,000,000 shares authorized
| - | 721,598 issued and outstanding
| - | Par value - $0.001
| - | Voting at 250 votes per share (180,399,500 votes)
| - | Ranks junior to any other class of preferred stock
| - | Dividends – equal to the per share amount (as converted basis) as the common stockholders should the Board of Directors declare a dividend
| - | Liquidation preference – original issue price plus any declared yet unpaid accrued dividends
| - | Rights of redemption - none
| - | Conversion into 250 shares of common stock for each share held (180,399,500 common stock equivalents)
|  | In October 2021, prior to the reverse stock split, all Series C stockholders representing 721,598 shares issued and outstanding agreed to convert their holdings into common stock. The conversion was based upon the expected 1 for 50 reverse stock split which occurred on November 2, 2021. As a result of the conversion, the Company issued 3,607,980 shares of common stock. The net effect on equity was $0.
SURGEPAYS, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2021 Equity Transactions for the Nine Months Ended September 30, 2021 Reverse Stock Split On November 2, 2021, the Company effected a 1 for 50 reverse stock split. All share and per share amounts have been retroactively restated to the earliest period presented. Stock Issued for Cash The Company issued 260,000 shares of common stock for $1,510,000 ($5 -$8/share). Stock Issued for Services The Company issued 9,991 shares of common stock for services rendered, having a fair value of $79,505 ($5 - $14.05/share), based upon the quoted closing trading price. Exercise of Warrants The Company issued 2,133 shares of common stock in connection with a cashless exercise of warrants. The transaction had a net effect of $0 on stockholders’ deficit. Stock Issued as Debt Discount The Company issued 18,000 shares of common stock in connection with the issuance of debt, having a fair value of $2,038,635 ($5.35/share), based upon the quoted closing trading price. Warrants Issued as a Debt Discount The Company issued 2,406,250 three (3) year warrants, having an exercise price of $8/share, with notes totaling $386,000, resulting in a debt discount of $265,268. The notes had an original issue discount of $36,000 as well as warrants that were accounted for at fair value totaling $229,268. Fair value of the warrants was determined using a Black-Scholes option pricing model with the following inputs: Schedule of Fair Value of The Warrants
Expected term (years) |  |  | 3 years |
Expected volatility |  |  | 118 | %
Expected dividends |  |  | 0 | %
Risk free interest rate |  |  | 0.53 | %
SURGEPAYS, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2021 Conversion of Debt The Company issued 147,916 shares of common stock in connection with the conversion of convertible debt, having a fair value of $948,002 ($3.40 - $10.40/share), based upon the quoted closing trading price. Make-whole Arrangement The Company issued 15,147 shares of common stock to debt holders that were entitled to shares upon the settlement of debt and related accrued interest. The shares had a fair value of $90,401 ($5.60 - $6/share), based upon the quoted closing trading price. Stock Issued for Debt Modification The Company issued 13,916 shares of common stock in connection with the modification of debt arrangements. The shares had a fair value of $108,931 ($5.60 - $8/share), based upon the quoted closing trading price. Stock Issued in Settlement of Liabilities The Company issued 276,702 shares of common stock to various vendors and debt holders to settle accounts payable, debt and derivative liabilities. The shares had a fair value of $1,879,785 ($4.50 - $13.50/share), based upon the quoted closing trading price. In connection with these debt settlements, the Company recorded a gain of $979,469. Stock Issued in Acquisition of Membership Interest in ECS On January 30, 2020, the Company entered into a Membership Interest Purchase Agreement and Stock Purchase Agreement with ECS Prepaid, ECS, CSLS and the Winfrey’s. Pursuant to the agreements, the Company acquired all of the membership interests of ECS Prepaid and all of the issued and outstanding stock of each ECS and CSLS. The agreements provide that the consideration is to be paid by the Company through the issuance of 10,000 shares of the Company’s Common Stock. In addition, the agreements called for 500 shares of Common Stock to be issued to the Winfrey’s on a monthly basis over a 12-month period. During the three months ended March 31, 2021, the Company issued 2,000 shares of Common Stock in full settlement of the agreements. The shares had a fair value of $17,900 ($8.95/share), based upon the quoted closing trading price. SURGEPAYS, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2021 Stock Options Stock option transactions under the Company’s Plan for the nine months ended September 30, 2021 and the year ended December 31, 2020 are summarized as follows: Schedule of Stock Option Transactions
|  |  |  |  |  |  |  | Weighted |  |  |  |  |  | Weighted |
|  |  |  |  |  |  |  | Average |  |  |  |  |  | Average |
|  |  |  |  | Weighted |  |  | Remaining |  |  | Aggregate |  |  | Grant |
|  | Number of |  |  | Average |  |  | Contractual |  |  | Intrinsic |  |  | Date |
Stock Options |  | Options |  |  | Exercise Price |  |  | Term (Years) |  |  | Value |  |  | Fair Value |
Outstanding - December 31, 2019 |  |  | - |  |  | $ | - |  |  |  | 0.00 |  |  | $ | - |  |  | $ | - |
Exercisable - December 31, 2019 |  |  | - |  |  | $ | - |  |  |  | 0.00 |  |  | $ | - |  |  | $ | - |
Vested and Exercisable - December 31, 2020 |  |  | - |  |  | $ | - |  |  |  | 0.00 |  |  | $ | - |  |  | $ | - |
Unvested and non-exercisable - December 31, 2020 |  |  | - |  |  | $ | - |  |  |  | 0 |  |  | $ | - |  |  | $ | - |
Granted |  |  | 17,004 |  |  | $ | 16.00 |  |  |  | 7.00 |  |  | $ | - |  |  | $ | 8.75 |
Exercised |  |  | - |  |  | $ | - |  |  |  |  |  |  | $ | - |  |  |  |  |
Cancelled/Forfeited |  |  | - |  |  | $ | - |  |  |  |  |  |  | $ | - |  |  |  |  |
Outstanding - December 31, 2020 |  |  | 17,004 |  |  | $ | 16.00 |  |  |  | 6.16 |  |  | $ | - |  |  | $ | - |
Vested and Exercisable - December 31, 2020 |  |  | - |  |  | $ | - |  |  |  | 0.00 |  |  | $ | - |  |  | $ | - |
Unvested and non-exercisable - December 31, 2020 |  |  | 17,004 |  |  | $ | 16.00 |  |  |  | 6.16 |  |  | $ | - |  |  | $ | - |
Outstanding - December 31, 2020 |  |  | 17,004 |  |  | $ | 16.00 |  |  |  | 6.16 |  |  | $ | - |  |  | $ | - |
Vested and Exercisable - December 31, 2020 |  |  | - |  |  | $ | - |  |  |  | 0.00 |  |  | $ | - |  |  | $ | - |
Unvested and non-exercisable - December 31, 2020 |  |  | 17,004 |  |  | $ | 16.00 |  |  |  | 6.16 |  |  | $ | - |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |  |  | $ | - |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Cancelled/Forfeited |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding - September 30, 2021 |  |  | 17,004 |  |  | $ | 16.00 |  |  |  | 5.42 |  |  | $ | - |  |  | $ | - |
Vested and Exercisable - September 30, 2021 |  |  | 3,401 |  |  | $ | 16.00 |  |  |  | 5.42 |  |  | $ | - |  |  | $ | - |
Unvested and non-exercisable - September 30, 2021 |  |  | 13,603 |  |  | $ | 16.00 |  |  |  | 5.42 |  |  | $ | - |  |  | $ | - |
Compensation expense recorded for stock-based compensation is as follows for the nine months ended September 30, 2021 and 2020, respectively: Schedule of Stock-based Compensation
Nine Months Ended |
September 30, 2021 |  |  | September 30, 2020 |
$ | 27,880 |  |  | $ | 21,685 |
SURGEPAYS, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2021 As of September 30, 2021, compensation cost related to the unvested options not yet recognized was as follows: Schedule of Unvested Options Not Yet Recognized
Compensation expense |  | $ | 89,837 |
Weighted average period in which compensation will vest (years) |  |  | 2.42 |
The unvested stock option expense is expected to be recognized through March 2024. Warrants Warrant activity for the Nine Months Ended September 30, 2021 and the Year Ended December 31, 2020 are summarized as follows: Schedule of Warrants Activity
|  |  |  |  |  |  |  | Weighted |  |  |  |
|  |  |  |  |  |  |  | Average |  |  |  |
|  |  |  |  | Weighted |  |  | Remaining |  |  | Aggregate |
|  | Number of |  |  | Average |  |  | Contractual |  |  | Intrinsic |
Warrants |  | Warrants |  |  | Exercise Price |  |  | Term (Years) |  |  | Value |
Outstanding and exercisable - December 31, 2019 |  |  | 136,993 |  |  | $ | 35.50 |  |  |  | 1.98 |  |  | $ | - |
Exercisable |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Granted |  |  | 62,325 |  |  | $ | 26.50 |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cancelled/Forfeited |  |  | (5,000 | ) |  | $ | 40.00 |  |  |  | - |  |  |  | - |
Outstanding - December 31, 2020 |  |  | 194,317 |  |  | $ | 32.50 |  |  |  | 1.52 |  |  | $ | - |
Exercisable - December 31, 2020 |  |  | 194,317 |  |  | $ | 32.50 |  |  |  | 1.52 |  |  | $ | - |
Outstanding - December 31, 2020 |  |  | 194,317 |  |  | $ | 32.50 |  |  |  | 1.52 |  |  | $ | - |
Exercisable - December 31, 2020 |  |  | 194,317 |  |  | $ | 32.50 |  |  |  | 1.52 |  |  | $ | - |
Granted |  |  | 326,075 |  |  | $ | 8.13 |  |  |  | - |  |  |  | - |
Exercised |  |  | (2,133 | ) |  |  | 12.50 |  |  |  | - |  |  |  | - |
Cancelled/Forfeited |  |  | (44,650 | ) |  | $ | 23.49 |  |  |  | - |  |  |  | - |
Outstanding - September 30, 2021 |  |  | 473,609 |  |  | $ | 16.68 |  |  |  | 3.21 |  |  | $ | - |
Exercisable - September 30, 2021 |  |  | 473,609 |  |  | $ | 16.68 |  |  |  | 3.21 |  |  | $ | - |
During 2021, the Company granted 277,950 warrants to convertible note holders and additional 48,125 warrants to note holders. These warrants were exercisable upon grant, had expiration dates ranging from 3 – 5 years, and an exercise price of $8/share. SURGEPAYS, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2021

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration